Payment overview · 2025
General Payments
$32,426.50
199 reported records · 15 companies
Healthcare provider profile · identity verified
Tanis Bast
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · UNION, MO · NPI 1295193274
Verified facts
What the public records show
CMS Open Payments records show Tanis Bast received $32,426.50 in general payments during 2025 across 199 reported records.
Alkermes, Inc. accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brixadi, Sublocade, Vivitrol.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Vivitrol by this doctor in 2024.
Braeburn Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRIXADI as an associated drug or biological on 15883 records involving 5757 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brixadi by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Sublocade by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21,151.13 | 65.2% | 48 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $9,525.99 | 29.4% | 46 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $317.57 | 1.0% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $298.94 | 0.9% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $261.55 | 0.8% | 14 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $219.07 | 0.7% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $158.06 | 0.5% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $149.93 | 0.5% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.18 | 0.3% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $83.80 | 0.3% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $68.53 | 0.2% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $43.18 | 0.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.07 | 0.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.69 | 0.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.81 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,860.00 | 8 |
| Honoraria | $5,962.50 | 6 |
| Travel and Lodging | $5,343.24 | 25 |
| Food and Beverage | $3,700.76 | 159 |
| Consulting Fee | $560.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $21,072.39 | 41 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $9,525.99 | 46 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $321.25 | 17 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $298.94 | 20 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $261.55 | 14 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $219.07 | 14 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $158.06 | 13 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $149.93 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $85.18 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $80.12 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $80.12 | 4 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $78.74 | 7 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $78.74 | 7 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $68.53 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $43.18 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRIXADI brixadi |
2025 | Brixadi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIVITROL vivitrol |
2025 | Vivitrol | 2024 | 106 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
106 | 24 |
| Braeburn Inc. Exact reporting entity; no affiliate inference |
2025 | BRIXADI open payments reported associated product |
CMS Open Payments — General Payments 15883 supporting records · 5757 recipient NPIs · example record 1249056386 |
Brixadi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 210 | 29 |
| Vivitrol | Naltrexone Microspheres | 106 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 43 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 37 | 23 |
| Sublocade | Buprenorphine | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Brixadi | Buprenorphine | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $32,426.50 · 199 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, Auvelity, BRIXADI, CAPLYTA, COBENFY, Dexcom G6 Transmitter, FANAPT, GVOKE HYPOPEN, LYBALVI, REXULTI, SUBLOCADE, UZEDY, VIVITROL, VRAYLAR, XIFAXAN, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brixadi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error